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SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comResults: Device deployment was attempted in all animals, of which 100% of NG-WM
(6/6) and 75%ofCG-WM(6/8) were successfully deployed. Two animals were excluded
due to pericardial effusion and unfavorable LAA anatomy. All implanted animals were
well tolerated the procedure and without adverse cardiac or systemic events. The table
summarizes the overall deployment parameters between the two generation devices.
Conclusions: The next generation of the WATCHMAN device showed an
improvement in the ease of implant. The NG-WM procedure required fewer device
partial or full recaptures. Furthermore, the additional struts on the NG-WM device
showed better seal with less leaks than the CG-WM, though neither device showed
residual leaks in excess of 2 mm. Long-term assessment of device interaction with
biologic systems and how the biologic system may affect the device study is ongoing.CG-WM NG-WM
Dogs 6 6
Total devices used 10 6
Full recaptures required in dogs 4 0
Partial recaptures in dogs 3 1
Peri-device jet (<2mm) in dogs 2 0TCT-176
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Background: Left atrial appendage closure (LAAC) is, intuitively, an attractive
strategy to reduce stroke risk in atrial ﬁbrillation. Although the PROTECT-AF trial
demonstrated superiority of the WATCHMANTM LAAC device over warfarin at four
years, there is little data regarding ischemic stroke protection of LAAC therapy in
patients unable or unwilling to take warfarin. We sought to assess the effectiveness of
the device for stroke risk reduction compared to the imputed placebo event rate, that
is, the expected ischemic stroke rate without anticoagulation therapy, based on
CHADS2 score, in three separate device trials.
Methods: The imputed placebo event rate in the trials (PROTECT AF, CAP, PRE-
VAIL) was calculated using the average CHADS2 score in each study. The expected
event rate, which is well validated in the literature, was compared with the observed
ischemic stroke rate in the device arm of each individual trial.
Results: Patients from PROTECT AF (n¼463), CAP (n¼566) and PREVAIL
(n¼407) were analyzed. The average CHADS2 score and imputed placebo event rate
per 100 patient-years were 2.2 (5.6-5.7), 2.5 (6.4), and 2.6 (6.6-6.7) in PROTECT AF,
CAP, and PREVAIL, respectively. The relative risk reduction for ischemic stroke was
77%, 83%, and 62%, respectively (Table).
Conclusions: In this analysis, LAAC with WATCHMAN is associated with a sig-
niﬁcant reduction in ischemic stroke compared with an expected event rate derived
from the CHADS2 score. The relative risk reduction is similar to that seen in the
historical trials comparing warfarin to placebo, suggesting LAAC may provide a
reduction in stroke risk for patients not receiving anticoagulation therapy.Imputed Placebo versus Observed WATCHMAN Ischemic Stroke Rate per 100
Patient - Years
Study
Average
CHADS2
Score
WATCHMAN
Patients
Imputed
Untreated
Control
Event Rate
Observed
WATCHMAN
Ischemic Stroke
Rate (95% CI)
Relative Risk
Reduction
PROTECT
AF
2.2 5.6 to 5.7 1.3 (0.9, 2.0) 77% (64%, 84%)
CAP 2.5 6.4 1.1 (0.8, 1.7) 83% (73%, 88%)
PREVAIL 2.6 6.6 to 6.7 2.5 (1.5, 4.3) 62% (35%, 77%)TCT-177
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Hamburg, Germany, 5Cardiologicum Hamburg, Hamburg, GermanyB52 JACC Vol 64/11/Suppl B j SepBackground: Patient selection and postinterventional anticoagulation after
WATCHMAN implantation varies widely between centers and national guidelines.
Clinical data are available mainly for relatively low risk patients and only in com-
parison to warfarin, whereas direct oral anticoagulants gain an increasing role in
clinical practice. Here, we present follow-up data after WATCHMAN implantation
in a high-risk population in terms of safety and efﬁcacy from our all-comers ALSTER-
LAA registry and compare these to subgroup analyses from the ARISTOTLE trial
showing safety and efﬁcacy of apixaban in patient at particular high risk for stroke and
bleeding events.
Methods: Postinterventional anticoagulation according to the individual bleeding risk
and conducted either with warfarin, DAPT or low-dose DOACS. Follow-up TEE after
3 months and regular clinical follow-ups thereafter.
Results: Between 2010 andApril 2014, 196 patients were treatedwithWATCHMAN
devices in our center, regular follow-up data is availeable for 110 patients. Mean follow-
up duration was 396 (33) days. Mean age: 74.6 years (0.9), CHA2DS2-VASc-Score
4.7 (0.2), HAS-BLED score 3.7 (0.1). In 109 patients (99%) LAA occlusion was
successfully performed using the WATCHMAN device. We observed two peri-
procedural strokes (1.8%), one device embolization (0.9%) and three relevant pericardial
effusions (2.7%). In addition, we observed 2 strokes, 9 cv or unknowndeaths and 2major
bleedings as endpoints during our follow-up (rates shown in ﬁgure 1). The combined
safety endpoint (procedure-related stroke, bleeding, pericardial effusion, device
embolization and major bleeding) and combined efﬁcacy endpoint (stroke, systemic
embolism and cardiovascular/unknown death) are calculated as in PROTECT-AF.
Conclusions:  LAA occlusion with the WATCHMAN device can yield similar re-
sults in “real world” collective as in PROTECT-AF  NOACs are not an effective
alternative to VKA for patients at high bleeding risk  Comparison with high-risk
subgroups from NOAC trials (ARISTOTLE) imply, that WATCHMAN will keep its
signiﬁcance even with increasing useage of NOACs
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Background: PercutaneousLeft atrial appendage (LAA) closure is emerging as a safe and
effective alternative to medical anticoagulation for embolic event prophylaxis in non-
valvular atrialﬁbrillation.However, the effectivenessof theprocedure inpatientswith atrial
ﬁbrillation secondary to or associated valvular heart disease is not proven.We hypothesize
that majority of patients with atrial ﬁbrillation associated with severe aortic stenosis could
be candidates for the procedure due to the location of thrombus being the LAA.
Methods: We queried our institutional echocardiography database from January 2003
to December 2012. All patients with aortic valve area less than 1.3 cm2 and who had a
current episode or previous history of atrial ﬁbrillation were considered for inclusion.
Patients were excluded if no thrombus or echo contrast sludge was detected in the left
atrium on trans-esophageal echocardiography (TEE). Descriptive statistics were used
to summarize the data.
Results: Of the 185 patients whomet the inclusion criteria, 73 (41%) patients also had an
associated mitral valve disease. As shown in the attached ﬁgure 60% patients had a
deﬁnitive thrombus visible on echocardiogram and only 2%of the patients whowere free
of associated mitral valve disease had a deﬁnitive thrombus detected in left atrial cavity.Conclusions: Our analysis suggests that in patients with aortic stenosis, free of
associated mitral valve disease, only a small number of thrombi are formed in left
atrial cavity. This could imply that majority of these patients may beneﬁt from
percutaneous left atrial appendage closure.tember 13–17, 2014 j TCT Abstracts/Left Atrial Appendage Exclusion
